Patents by Inventor Christoph Saal

Christoph Saal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline modifications of N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts
    Patent number: 10981864
    Abstract: The present invention relates to novel crystalline modifications of N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride, novel N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts and their crystalline modifications and processes of manufacturing and pharmaceutical formulations thereof.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: April 20, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Axel Becker, Gilmary Gallon, Christoph Saal, Clemens Kuehn
  • Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone
    Patent number: 10689363
    Abstract: A solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, are useful as BTK inhibitors.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: June 23, 2020
    Assignee: Merck Patent GmbH
    Inventors: Axel Becker, Marco Poma, Edoardo Burini, Christoph Saal, Vedad Theuerkorn
  • Process for producing of inorganic particulate material
    Patent number: 10577250
    Abstract: The present invention is directed to a process for producing inorganic particulate material, the material obtainable by such process, a modified release delivery system comprising the material and the use of the material for the administration of a bioactive agent.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: March 3, 2020
    Assignee: Merck Patent GmbH
    Inventors: Mario Maio, Eugenia Breininger, Karin Cabrera Perez, Ulrich Lang, Benjamin Peters, Thomas Puchert, Christoph Saal, Michael Schulz
  • NOVEL CRYSTALLINE FORMS OF 1-(4-{[6-AMINO-5-(4-PHENOXY-PHENYL)-PYRIMIDIN-4-YLAMINO]-METHYL}-PIPERIDIN-1-YL)-PROPENONE
    Publication number: 20200017464
    Abstract: A solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, are useful as BTK inhibitors.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 16, 2020
    Inventors: Axel BECKER, Marco Poma, Edoardo Burini, Christoph Saal, Vedad Theuerkorn
  • Crystalline Modifications of N-(4,5-Bismethanesulfonyl-2-Methylbenzoyl)Guanidine Hydrochloride and N-(4,5-Bismethanesulfonyl-2-Methylbenzoyl)Guanidine Salts
    Publication number: 20190345100
    Abstract: The present invention relates to novel crystalline modifications of N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride, novel N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts and their crystalline modifications and processes of manufacturing and pharmaceutical formulations thereof.
    Type: Application
    Filed: January 27, 2017
    Publication date: November 14, 2019
    Inventors: AXEL BECKER, GILMARY GALLON, CHRISTOPH SAAL, CLEMENS KUEHN
  • Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone
    Patent number: 10464923
    Abstract: The present invention relates to a solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: November 5, 2019
    Assignee: Merck Patent GmbH
    Inventors: Axel Becker, Marco Poma, Edoardo Burini, Christoph Saal, Vedad Theuerkorn
  • NOVEL CRYSTALLINE FORMS OF 1-(4-{[6-AMINO-5-(4-PHENOXY-PHENYL)-PYRIMIDIN-4-YLAMINO]-METHYL}-PIPERIDIN-1-YL)-PROPENONE
    Publication number: 20190010142
    Abstract: The present invention relates to a solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, useful as BTK inhibitors.
    Type: Application
    Filed: February 22, 2018
    Publication date: January 10, 2019
    Inventors: Axel BECKER, Marco POMA, Edoardo BURINI, Christoph SAAL, Vedad THEUERKORN
  • PROCESS FOR PRODUCING OF INORGANIC PARTICULATE MATERIAL
    Publication number: 20170049892
    Abstract: The present invention is directed to a process for producing inorganic particulate material, the material obtainable by such process, a modified release delivery system comprising the material and the use of the material for the administration of a bioactive agent.
    Type: Application
    Filed: November 8, 2016
    Publication date: February 23, 2017
    Applicant: Merck Patent GmbH
    Inventors: Mario Maio, Eugenia Breininger, Karin Cabrera Perez, Ulrich Lang, Benjamin Peters, Thomas Puchert, Christoph Saal, Michael Schulz
  • Process for producing inorganic particulate material
    Patent number: 9517268
    Abstract: The present invention is directed to a process for producing inorganic particulate material, the material obtainable by such process, a modified release delivery system comprising the material and the use of the material for the administration of a bioactive agent.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: December 13, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Mario Maio, Eugenia Breininger, Karin Cabrera Perez, Ulrich Lang, Benjamin Peters, Thomas Puchert, Christoph Saal, Michael Schulz
  • Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyrdazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
    Patent number: 9308205
    Abstract: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: April 12, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Axel Becker, Clemens Kuehn, Christoph Saal, Oliver Schadt, Dieter Dorsch, Heinz-Hermann Bokel, Frank Stieber, Cristina Donini
  • Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-hydrochloride salt and processes of manufacturing thereof
    Patent number: 9289427
    Abstract: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: March 22, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Axel Becker, Clemens Kuehn, Christoph Saal, Oliver Schadt, Dieter Dorsch, Heinz-Hermann Bokel, Frank Stieber, Cristina Donini
  • Solid state forms of N-((S)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
    Patent number: 9260393
    Abstract: The invention relates to solid state forms of N—((S)-2,3-Dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide, processes for their preparation, and medical uses thereof.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: February 16, 2016
    Assignee: Merck Patent GmbH
    Inventors: Axel Becker, Christoph Saal, Clemens Kuehn, Donald Bankston, Marco Poma
  • USE OF SILICON OXIDE-BASED MATERIAL FOR THE MODIFIED RELEASE OF BIOLOGICALLY ACTIVE AGENTS
    Publication number: 20150283090
    Abstract: The present invention is directed to the use of a composite silicon oxide-based material for the modified release of biologically active agents.
    Type: Application
    Filed: October 14, 2013
    Publication date: October 8, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Karin Cabrera, Ulrich Lang, Benjamin Peters, Christoph Saal, Michael Schulz, Dieter Lubda, Shawn Kucera
  • SOLID STATE FORMS OF N-((S)-2,3-DIHYDROXY-PROPYL)-3-(2-FLUORO-4-IODO-PHENYLAMINO)-ISONICOTINAMIDE
    Publication number: 20150152059
    Abstract: The invention relates to solid state forms of N—((S)-2,3-Dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide, processes for their preparation, and medical uses thereof.
    Type: Application
    Filed: May 7, 2013
    Publication date: June 4, 2015
    Applicant: Merck Patent GmbH
    Inventors: Axel Becker, Christoph Saal, Clemens Kuehn, Donald Bankston, Marco Poma
  • NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF
    Publication number: 20150148351
    Abstract: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Axel BECKER, Clemens KUEHN, Christoph SAAL, Oliver SCHADT, Dieter DORSCH, Heinz-Hermann BOKEL, Frank STIEBER, Cristina DONINI
  • PROCESS FOR PRODUCING INORGANIC PARTICULATE MATERIAL
    Publication number: 20140336274
    Abstract: The present invention is directed to a process for producing inorganic particulate material, the material obtainable by such process, a modified release delivery system comprising the material and the use of the material for the administration of a bioactive agent.
    Type: Application
    Filed: April 25, 2012
    Publication date: November 13, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Mario Maio, Eugenia Breininger, Karin Cabrera Perez, Ulrich Lang, Benjamin Peters, Thomas Puchert, Christoph Saal, Michael Schulz
  • NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF
    Publication number: 20140200221
    Abstract: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 17, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Axel BECKER, Clemens KUEHN, Christoph SAAL, Oliver SCHADT, Dieter DORSCH, Heinz-Hermann BOKEL, Frank STIEBER, Cristina DONINI
  • Solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them
    Patent number: 8765684
    Abstract: The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: July 1, 2014
    Assignee: Merck Patent GmbH
    Inventors: Alfred Jonczyk, Clemens Kuehn, Kerstin Seemann, Christoph Saal, Gerald Scholz, Soenke Petersen, Harald Untenecker, Michael Lange
  • Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
    Patent number: 8710058
    Abstract: Compounds of the present invention concern 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The compound, 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile, has the following structural formula: The hydrochloride solvates and crystalline modifications thereof according to the invention are useful for treatment of physiological and/or pathophysiological conditions, such as cancer, that are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, especially Met-kinase. The present invention further relates to processes of manufacturing these crystalline modifications.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: April 29, 2014
    Assignee: MERCK PATENT GmbH
    Inventors: Axel Becker, Clemens Kuehn, Christoph Saal, Oliver Schadt, Dieter Dorsch, Heinz Hermann Bokel, Frank Stieber, Cristina Donini
  • Novel Solid Materials of and Methods for Obtaining Them
    Publication number: 20140088022
    Abstract: The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals.
    Type: Application
    Filed: September 16, 2013
    Publication date: March 27, 2014
    Applicant: Merck Patent GmbH
    Inventors: Alfred Jonczyk, Clemens Kuehn, Kerstin Seemann, Christoph Saal, Gerald Scholz, Soenke Petersen, Harald Untenecker, Michael Lange